Nautilus Biotechnolgy, Inc. (NAUT)

Over the past six months, Nautilus Biotechnology, Inc.'s stock price has increased significantly. Key events include reporting First Quarter 2026 Financial Results with a narrower net loss, participation in the Investor Summit Group Virtual Conference, and the announcement of Baylor College of Medicine as the first Early Access Program customer for its Voyager Platform. Amber Faust was appointed as Vice President of Sales, and the company reported its Fourth Quarter and Fiscal Year 2025 Financial Results. Goldman Sachs downgraded NAUT to Sell, citing skepticism about the company's ability to meet its commercialization timeline, while CEO Sujal M. Patel bought 25,000 shares.

As a development-stage life sciences company, Nautilus Biotechnology, Inc. does not yet have established demand seasonality for its products and services. Information regarding seasonal patterns in the demand for its specific products is not available, likely due to their pre-commercialization status.

Nautilus Biotechnology, Inc. is a development-stage life sciences company in the Health Technology sector, focusing on Biotechnology and Life Sciences Tools and Services. The company is developing a platform technology to quantify and unlock the human proteome, aiming to democratize access and advance human health. Its major offerings center around the Nautilus Voyager Platform, an end-to-end solution that includes a Proteome Analysis System, Reagent Kits, and Software and analysis tools.

Nautilus Biotechnology, Inc. is headquartered in Seattle, Washington, United States, with primary operations based in the United States. It engages in strategic research collaborations with various institutions, including Genentech, the Buck Institute for Research on Aging, the Allen Institute, Baylor College of Medicine, Cornell University, the Qatar Foundation, and the Michael J. Fox Foundation.

Nautilus Biotechnology's brand reputation has been influenced by positive developments and some skepticism. Positive events include establishing research collaborations with prominent institutions, the announcement of Baylor College of Medicine as the first Early Access Program customer for its Voyager Platform, and successful installation and testing of its first field evaluation unit at the Buck Institute for Research on Aging. A notable event that could have negatively impacted its reputation was Goldman Sachs' downgrade of NAUT to Sell, reflecting concerns about the company's ability to meet its commercialization timeline.

Nautilus Biotechnology, Inc. has a diverse ownership structure. Institutional owners hold approximately 45.41% to 46.15% of the shares, while individuals hold around 32.34% to 73.47%. Major institutional shareholders include AH Capital Management, L.L.C., Perceptive Advisors Llc, Cercano Management LLC, Madrona Venture Group, LLC, Vanguard Group Inc, Amazon Com Inc, BlackRock, Inc., Goldman Sachs Group Inc., Dimensional Fund Advisors LP and Citizens Financial Group Inc. RI. Key individual owners include Parag Mallick, Sujal M. Patel, Vijay Satyanand Pande, and Matthew S. McIlwain.